Jasper Therapeutics (NASDAQ:JSPR) Shares Gap Down – Here’s Why

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) gapped down prior to trading on Friday. The stock had previously closed at $14.0760, but opened at $12.76. Jasper Therapeutics shares last traded at $15.8740, with a volume of 47,986 shares.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Wall Street Zen raised Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Piper Sandler began coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They issued an “overweight” rating and a $60.00 price objective for the company. HC Wainwright restated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. William Blair assumed coverage on shares of Jasper Therapeutics in a research note on Wednesday, October 14th. They set an “outperform” rating on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $220.00.

Jasper Therapeutics Stock Up 14.0%

The firm has a market capitalization of $534.13 million, a price-to-earnings ratio of -10.03 and a beta of 3.30. The business’s 50-day simple moving average is $0.58 and its two-hundred day simple moving average is $0.84.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Friday, August 14th. The company reported ($3.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($8.03) by $5.03. Sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.